IN184589B
(tr)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
EP2420247A1
(en)
*
|
2000-03-07 |
2012-02-22 |
Merck Sharp & Dohme Corp. |
Adenovirus formulations
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
AU2002361545B2
(en)
*
|
2001-06-28 |
2007-03-15 |
Microchips, Inc. |
Methods for hermetically sealing microchip reservoir devices
|
AU2002353013A1
(en)
|
2001-12-03 |
2003-06-17 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
KR101076335B1
(ko)
*
|
2002-03-13 |
2011-10-26 |
토마스 스쾰트 |
수성-기재 전달계
|
WO2004071487A2
(en)
*
|
2002-08-16 |
2004-08-26 |
Microchips, Inc. |
Controlled release device and method
|
US7497855B2
(en)
*
|
2002-09-04 |
2009-03-03 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
PL212483B1
(pl)
*
|
2002-09-27 |
2012-10-31 |
Powderject Res Ltd |
Sposób wytwarzania czasteczek, czasteczki odpowiednie do dostarczania, pojemnik, urzadzenie do dostarczania czasteczek i zastosowanie tych czasteczek
|
WO2004033034A1
(en)
|
2002-10-04 |
2004-04-22 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
WO2004057959A2
(en)
*
|
2002-12-20 |
2004-07-15 |
Generipharm, Inc. |
Intracutaneous injection
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
EP1638522B1
(en)
*
|
2003-04-25 |
2011-01-12 |
Boston Scientific Scimed, Inc. |
Solid drug formulation and device for storage and controlled delivery thereof
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
EP1694200B1
(en)
*
|
2003-11-03 |
2010-09-29 |
MicroCHIPS, Inc. |
Medical device for sensing glucose
|
WO2006085908A2
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
US7537590B2
(en)
*
|
2004-07-30 |
2009-05-26 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
EP1791643B1
(en)
*
|
2004-09-01 |
2009-03-11 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
ES2701090T3
(es)
|
2004-09-10 |
2019-02-20 |
Becton Dickinson Co |
Dispositivo de reconstitución de infusión y método de reconstitución de medicamento
|
WO2006081279A2
(en)
|
2005-01-25 |
2006-08-03 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US9301919B2
(en)
*
|
2005-12-22 |
2016-04-05 |
Oakwood Laboratories, Llc |
Sublimable sustained release delivery system and method of making same
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
US7682356B2
(en)
|
2006-08-09 |
2010-03-23 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies for use therein
|
EP2134353B1
(en)
*
|
2007-03-30 |
2016-11-16 |
Helix Biopharma Corp. |
Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス,インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
JP5658031B2
(ja)
|
2007-06-22 |
2015-01-21 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
JP5711138B2
(ja)
|
2008-11-16 |
2015-04-30 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
高濃度の低粘度懸濁液
|
EP3936122A1
(en)
*
|
2008-11-24 |
2022-01-12 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
JP5837519B2
(ja)
*
|
2010-03-09 |
2015-12-24 |
ヤンセン バイオテツク,インコーポレーテツド |
非水性高濃度減粘懸濁製剤
|
EP2547323B1
(en)
|
2010-03-17 |
2016-01-27 |
Novaliq GmbH |
Pharmaceutical composition for treatment of increased intraocular pressure
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EA028572B1
(ru)
|
2011-03-10 |
2017-12-29 |
Ксерис Фармасьютикалс, Инк. |
Стабильная композиция для парентеральной инъекции и способы ее получения и использования
|
CA2834855C
(en)
|
2011-05-25 |
2020-12-29 |
Novaliq Gmbh |
Topical pharmaceutical composition based on semifluorinated alkanes
|
EP2714008B1
(en)
|
2011-05-25 |
2016-12-14 |
Novaliq GmbH |
Pharmaceutical composition for administration to nails
|
AU2012332556B2
(en)
|
2011-10-31 |
2016-05-26 |
Xeris Pharmaceuticals, Inc. |
Formulations for the treatment of diabetes
|
DK2806886T3
(en)
|
2012-01-23 |
2017-06-06 |
Novaliq Gmbh |
STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
AU2013314303B2
(en)
|
2012-09-12 |
2018-01-18 |
Novaliq Gmbh |
Semifluorinated alkane compositions
|
MX363182B
(es)
|
2012-09-12 |
2019-03-13 |
Novaliq Gmbh |
Composiciones que comprenden mezclas de alcanos semifluorados.
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
EP3712142B1
(en)
|
2013-01-11 |
2022-07-06 |
Corsair Pharma, Inc. |
Prodrugs of treprostinil
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
AU2014228938B2
(en)
*
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
JP6503349B2
(ja)
|
2013-07-23 |
2019-04-17 |
ノバリック ゲーエムベーハー |
安定化された抗体組成物
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
CN110496099B
(zh)
|
2013-09-11 |
2022-06-21 |
伊戈尔生物药品股份有限公司 |
包含粘度降低剂的液体蛋白质制剂
|
EP3049114B1
(en)
|
2013-09-27 |
2021-11-10 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
MX2016012447A
(es)
*
|
2014-03-24 |
2017-01-06 |
Biogen Ma Inc |
Formulaciones de factor ix liofilizadas.
|
EP3169660A1
(en)
|
2014-07-16 |
2017-05-24 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
JP6982495B2
(ja)
|
2014-08-06 |
2021-12-17 |
ゼリス ファーマシューティカルズ インコーポレイテッド |
ペーストの皮内および/または皮下注射のためのシリンジ、キット、および方法
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017004306A
(es)
|
2014-10-01 |
2017-12-20 |
Eagle Biologics Inc |
Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
JP6887685B2
(ja)
|
2015-08-12 |
2021-06-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
ナノ粒子の細胞表面共役
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
EP3495023B1
(en)
|
2015-09-30 |
2020-04-22 |
Novaliq GmbH |
Semifluorinated compounds and their compositions
|
US11154513B2
(en)
|
2015-09-30 |
2021-10-26 |
Novaliq Gmbh |
Semifluorinated compounds
|
WO2017200943A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
WO2017220625A1
(en)
|
2016-06-23 |
2017-12-28 |
Novaliq Gmbh |
Topical administration method
|
EP3515420B1
(en)
|
2016-09-22 |
2023-11-08 |
Novaliq GmbH |
Pharmaceutical compositions for use in the therapy of blepharitis
|
KR20190057338A
(ko)
|
2016-09-23 |
2019-05-28 |
노바리크 게엠베하 |
시클로스포린을 포함하는 안과 조성물
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
AU2018253944B2
(en)
|
2017-04-21 |
2022-09-15 |
Dermaliq Therapeutics, Inc. |
Iodine compositions
|
EP3621601A1
(en)
|
2017-05-12 |
2020-03-18 |
Novaliq GmbH |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
EP4378463A2
(en)
|
2017-06-02 |
2024-06-05 |
Xeris Pharmaceuticals, Inc. |
Precipitation resistant small molecule drug formulations
|
US11524033B2
(en)
|
2017-09-05 |
2022-12-13 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
US11723861B2
(en)
|
2017-09-27 |
2023-08-15 |
Novaliq Gmbh |
Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
|
US11896559B2
(en)
|
2017-10-04 |
2024-02-13 |
Novaliq Gmbh |
Opthalmic compositions comprising F6H8
|
WO2019166631A1
(en)
|
2018-03-02 |
2019-09-06 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
ES2974839T3
(es)
|
2018-10-12 |
2024-07-01 |
Novaliq Gmbh |
Composición oftálmica para el tratamiento de la enfermedad de ojos secos
|
CN113661006A
(zh)
|
2019-02-05 |
2021-11-16 |
林迪生物科学公司 |
分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
|
EP4069324A4
(en)
|
2019-12-06 |
2024-01-10 |
Guangzhou Bioseal Biotech Co., Ltd. |
FLUID FIBRINOGEN THROMBIN PASTE
|
WO2023044455A2
(en)
*
|
2021-09-16 |
2023-03-23 |
Team Medical Llc |
Rna stabilization
|